Skip to main content

Table 1 Effect of baseline severity and treatment on NIS-LL and NIS-LL muscle weakness slopes per month

From: Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

 

NIS-LL

NIS-LL muscle weakness

Effect

Coefficient

Standard error

p-value

Coefficient

Standard error

p-value

Baselinea

0.0096

0.0016

< 0.0001

0.0119

0.0019

< 0.0001

Treatment groupb

 P-T during double-blind phase

0.3249

0.0453

0.0088c

0.1905

0.0360

0.0132c

 T-T during double-blind phase

0.1558

0.0448

 

0.0636

0.0356

 
  1. aRepresents the mean change in the slope per month associated with an increase in the respective baseline covariate equal to one unit
  2. bRepresents baseline-adjusted slope per month corresponding to the treatment group. Values for the open label phase of the extension study are not shown
  3. cp-value for slope comparison between tafamidis and placebo during the 18-month double-blind phase of the registration study
  4. NIS-LL Neuropathy Impairment Score − Lower Limbs; P-T placebo-to-tafamidis; T-T tafamidis-to-tafamidis